![]()
|
|
||||||||
J Biol Chem, Vol. 274, Issue 33, 23210-23214, August 13, 1999
From the The human tissue kallikrein (KLK)
family of serine proteases, which is important in post-translational
processing events, currently consists of just three genes The tissue or glandular kallikrein
(KLK)1,2
genes are members of a highly conserved multigene family encoding
serine proteases that are involved in the post-translational
modification of many polypeptides and are central to many biological
processes (reviewed in Refs. 1 and 2). The human KLK gene
family has previously been thought to contain only three members. These
are KLK1 encoding true tissue kallikrein (3-5),
KLK2 (6), and KLK3, or prostate specific antigen
(PSA) (7-9). The large size of this gene family in other species such
as rat and mouse, where kallikrein-like proteins are encoded by 13-24
genes (10-13), and the recent identification of a fragment of a
putative human kallikrein gene adjacent to the KLK2 gene on
a human genomic cosmid (14) suggested that the human KLK
gene family may be potentially larger than previously thought. Several
early estimations of the size of this family, using Southern analysis,
predicted just 3-4 genes (3, 5, 6, 15). However, heterologous probing
of a human genomic Southern blot with a monkey kallikrein cDNA
suggested that it may contain as many as 19 different genes (16).
Determination of the true size of the human gene family is important to
our understanding of the contribution of the kallikreins to human biology and their roles as peptide processing enzymes.
The three best characterized KLK families (human, rat, and
mouse) are all localized within gene clusters on single chromosomes. The human family currently spans 60 kb on chromosome 19q13.3-13.4 (17). The rat family, although in two clusters, is tightly linked at
one locus spanning 480 kb on chromosome 1 (11, 18, 19). Similarly, the
mouse kallikrein family has been localized to a single 310-kb locus on
chromosome 7, a position that is analogous to the human KLK
locus on chromosome 19 (4, 12, 20). Overall, these findings suggest
that if there are more members of the human kallikrein gene family they
should be localized within close proximity to the current
KLK locus on chromosome 19q13.3-13.4.
All kallikrein genes described to date are 5-7 kb in size and are
structurally identical in the genomic arrangement of the five exons and
four introns (2, 4, 6, 8, 10, 12, 13). The considerable homology shared
by members of these gene families, both within and between species,
suggests that they are derived from gene duplications, exon shuffling,
and subsequent divergence from a common ancestor (19, 21, 22). Whereas the rat and murine family members are highly homologous (74-89% protein similarity), the three fully characterized members of the human
family have lower homology (52-78% protein similarity), suggesting
that the human KLK gene family has diverged further than in
the rodent (1, 3-10, 12, 19). In support of this notion, three novel
serine proteases Thus, further characterization of the human KLK locus on
chromosome 19 will determine whether these novel kallikrein-related proteases are part of the human KLK family and also may
identify other members of this important family of serine proteases. We are currently mapping and sequencing several cosmids and BACs that span
over 430 kb surrounding the known KLK locus. A concurrent search of the expressed sequence tag (EST) data base for novel kallikrein-related sequences identified an EST sequence (EST 40886; accession number AA336074) from an endometrial carcinoma cDNA library that was 50% similar at the nucleotide level to the
exon2-exon3 regions of the three characterized human KLK
genes. We now report the cloning and mapping of the gene encoding this
kallikrein-related cDNA to the KLK locus. Although it
has also recently been described as a prostate-specific serine
protease, prostase (27), we have called this endometrial- and
prostate-expressed gene, KLK4, given its close relationship
to the other previously described KLK genes.
Cosmid DNA Clones--
Five cosmid clones (F24242, R28297,
F18306, F22702, R28781) that represent a region previously positive on
genomic Southern blots with the pHRK-1 KLK1 probe (4) were
used for the following studies. These cosmids span ~130 kb near the
q13.3-13.4 band junction on the metric
physical map of human chromosome 19.3 Using the Qiagen
Midiprep kit, DNA was isolated from these cosmids transformed in
Escherichia coli DH5a cells and grown in a 500-ml culture of
Luria-Bertani medium supplemented with 15 µg/ml chloramphenicol.
Genomic PCR--
Primers were designed from the putative exon 2 and exon 3 sequences of the endometrial carcinoma EST 40886 to amplify
this region, including intron 2, from the five cosmids as potential positive templates. PCR amplification was carried out in an Omnigene thermocycler with the following PCR conditions: 4 mM
MgCl2, 200 µM each deoxyribonucleoside
triphosphate, 10 ng of each primer, and 1.3 units of Taq
polymerase in 1× PCR buffer (Roche Biochemical). Cycling conditions
included an initial denaturation at 94 °C for 5 min, followed by 30 cycles of 94 °C for 30 s, 58 °C for 30 s, and 72 °C
for 30 s, with a final extension of 7 min at 72 °C. PCR
products were separated by electrophoresis through 1% agarose gels and
isolated using the Qiagen Gel Extraction kit.
Genomic Southern Analysis--
Cosmid DNA (10 µg) was digested
with the restriction enzyme EcoRI (Roche Biochemical) and
Southern blots were prepared using Hybond N+ nylon membrane
(Amersham Pharmacia Biotech) under standard conditions. Hybridizations
and washes were carried out at high stringency using the amplified
genomic fragment of EST 40886 (KLK4) (prepared by PCR as
described above) labeled with [ Subcloning and Sequencing of the Genomic KLK4 Clone--
The
KLK4 genomic PCR fragment from cosmid F22702 was subcloned
using the Promega pGEM-T Easy TM cloning kit and sequenced
fully with the ABI PRISMTM Dye Terminator cycle sequencing
Ready Reaction Kit (Perkin-Elmer) using 500 ng of plasmid and 3.2 pmol
of primer. Extension products were purified by ethanol precipitation
and analyzed using an automated Applied Biosystems 373A DNA Sequencer.
Further sequence was obtained by primer walking along F22702. Sequence
alignments were performed using the Align program at the Genestream
network server, IGH, France.
Amplification of EST 40886 Gene Sequence--
PCR analysis of the
five cosmids spanning the KLK locus, with EST 40886 specific
primers designed to putative exon 2 and 3 regions, identified a band of
~480 bp from the F22702 and R28781 cosmids (data not shown).
Comparison of the intron sizes of other kallikreins predicted that, if
this gene was in fact a kallikrein, this fragment could be up to 1.5 kb
in size. Although smaller than the predicted fragment, DNA sequencing
identified it as the expected product, and analysis of the sequence
indicated that the intron was in the correct position.
Sequence comparison of this intron with that of the
PSA intron 2 suggested that the difference in size was because of the
absence of Alu and MER repeat units within the novel genomic sequence
(data not shown).
KLK4 Gene Characterization--
The sequence of the
KLK4 gene, comprising the coding region and part of the 5'-
and 3'-noncoding sequence, was obtained by primer walking along the
F22702 cosmid and is shown in Fig. 1.
Comparison with the amino acid sequence, deduced from a cDNA isolated in parallel from a prostate cDNA library (data not shown), indicated that the KLK4 gene consists of five exons and four
introns, although the presence of a further upstream exon cannot be
ruled out. All of the intron/exon junctions conformed to the consensus sequence for eukaryotic splice sites and were in comparable positions to those of the other human KLK gene family members (Figs. 1
and 2). In addition, the exonic positions
of the serine protease catalytic triad residues (His-71, Asp-116,
Ser-207), the signal peptide, and the putative cleavage site of the
mature enzyme are common to all four KLK genes, although
KLK4 is missing a "kallikrein loop" region (Figs. 1 and
2). KLK4 encodes a 254-amino acid prepro-serine protease
that is 78% identical to pig enamel matrix serine protease and ~37%
identical to PSA, tissue kallikrein, and the K2 enzyme. The amino acid
sequence was identical to the serine protease sequence recently
reported as prostase (27) except for a Gln (Q) to His (H) change at
residue 197 that results from a single nucleotide change in the codon
(CAA to CAC). With the addition of the 3'-untranslated region from the
prostase cDNA sequence (27) (GenBankTM accession number
AF113140), the full size of the gene is estimated at ~5 kb, again
like that reported for the KLK1-3 genes (4, 6, 8).
Sequence Analysis of the 5'-flanking Region--
By comparison of
KLK4 with PSA, the sequence upstream of the KLK4
coding region can be presumed to include both the 5'-untranslated region of exon 1 and potential promoter sequence. This sequence lacks
any obvious TATA box, CAAT box or GC-rich regions, but the sequence at
KLK Gene Linkage--
Five cosmids that span the 170 kb of
chromosome 19q13.3-13.4 that incorporates the 60-kb kallikrein locus
were digested with EcoRI for Southern analysis.
Hybridization with the KLK4 cDNA sequence identified two
bands in cosmid F22702 of 4.3 and 0.5 kb and two bands of 9.26 and 0.5 kb from the adjacent R28781 cosmid (Fig.
3). The fainter hybridizing bands in
lanes 1-3 are cross-hybridization of the KLK1
and KLK3 genes located on these cosmids. The
EcoRI restriction fragments on each of the five cosmids that
were positive with the KLK1, KLK2, and KLK3
probes and two additional but small KLK-like fragments are
indicated in Fig. 4. Comparison of the
Southern analysis with the EcoRI restriction map of the
cosmid clones indicated that the KLK4 gene is located 25 kb
downstream of KLK2 (Fig. 4). Restriction enzyme analysis of
the KLK4 gene sequence obtained from the F22702 cosmid
identified an EcoRI site in the fifth exon. This indicates
that the KLK4 gene is transcribed on the reverse strand, in
a similar direction to KLK1 but the opposite direction to
KLK2 and KLK3. A comparison of these results with
the genomic sequence that is now available for other cosmids F25479 and
R333593 in this region confirms both the distance between
all four KLK genes and the direction of transcription.
In the data presented here, we have precisely defined, for the
first time, the locations of the three previously known KLK genes in the kallikrein gene locus on chromosome 19q13.3-13.4. In
addition we have identified, within the same locus, a fourth member of
this family of serine proteases that we have designated KLK4. Several criteria, which are particularly pertinent to
the rodent KLK/Klk families, have been used previously to
determine inclusion of a gene in this family. These are a high
conservation of sequence with the tissue kallikrein (KLK1)
gene, a similar genomic organization and size, and localization within
a cluster of related genes on the one chromosome in that species. As
noted below, the KLK4 gene fits all these criteria, although
in terms of sequence it would appear to have diverged further.
The KLK4 gene consists of five exons and four introns
spanning ~5.2 kb, a structure and size that is common to all members of the kallikrein gene families (reviewed in Ref. 1; see Refs. 2, 4, 6,
8, 10, 12, and 19). The exon-intron organization of serine protease
genes is well documented (32), with these genes being separated into
five different groups based on intron position and position of the
amino acid residues (His-71, Asp-116, Ser-207, chymotrypsin numbering)
that make up the catalytic triad. Several factors clearly indicate that
KLK4 belongs to the group that includes all the human
KLK family, as well as NES1 and trypsinogen. First, the
region encoding the signal peptide is in the first coding exon. Second,
the catalytic residues His-71 and Ser-207 are separated in different
exons and almost adjacent to the exon boundaries. Third, there is only
one intron between exons coding for the His-71 and Asp-116 catalytic
residues and, finally, the cleavage site in the zymogen or pro-enzyme,
that leads to activation of the mature enzyme, is localized
in the same exon as the His-71 residue.
Because the gene structure and coding sequence in all serine proteases,
including members of the trypsin family and the kallikreins, is very
similar, these genes are thought to have derived from a common ancestor
(19, 21, 22, 32). During evolution, some members of this ancestral gene
family have split to different chromosomes, e.g. trypsin to
chromosome 7 and tissue plasminogen activator to chromosome 8, but
KLK4 and the rest of the KLK gene family remain
close to each other on chromosome 19, suggesting that they constitute a
sub-family of these related serine proteases. Three Alu repeated
sequences are associated with the KLK2 gene: one in the
second intron and two approximately 0.4 and 1.2 kb upstream (33). Alu
and Mer repeats are also found in the second intron of PSA and
KLK1 in a very similar gene organization (4, 8) but the
KLK4 intron 2 lacks these repeat sequences. This suggests
that KLK4 may have separated from the ancestral serine protease gene before the formation of the rest of the kallikrein genes,
and it could possibly be a precursor to these other genes. Full
characterization of all KLK genes and other serine proteases in this locus will further clarify their relationships and the ultimate
size of this sub-family of serine proteases.
The human KLK gene family is clustered in a 60-kb region on
chromosome 19q13.3 -q13.4 in the order of
centromere-KLK1-KLK3-KLK2-telomere (17). From the chromosomal sequence that is now available for this
region, we have confirmed the distance from KLK1 to
KLK3 is at least 26 kb and from KLK3 to
KLK2 is 12 kb. We have mapped KLK4 25 kb
downstream of KLK2 and have determined that it is
transcribed in a similar direction to KLK1, in the opposite
direction to PSA and KLK2. Two KLK-like fragments
(KLK Frag #1, KLK Frag #2), also identified
(14)4 between KLK2
and KLK4, do not appear to date to be part of full-length genes and may constitute pseudo-genes. Two other serine protease genes
have also been mapped close to the human KLK gene family. Fluorescence in situ hybridization, somatic cell, and
radiation hybrid mapping have localized the recently identified NES1
gene to chromosome 19q13.3 (26), although its precise distance from the
current KLK genes is not known. A second serine protease
gene, Protease M (also known as zyme and neurosin) (23, 24) was also
localized to this same 19q13.3.-13.4 region by fluorescence in
situ hybridization. (23). These authors suggested that this gene
is also close to the KLK locus and proposed that the order of these genes is
centromere-ProteaseM-Nes1-KLK1-PSA-KLK2-19-telomere. Although the information gained from radiation hybrid and somatic cell
mapping and fluorescent in situ hybridization is less
precise than the restriction mapping and sequencing approach that we
have employed, it is likely that these two genes (NES1 and protease M)
are still part of a larger KLK cluster in this locus, akin to that seen in the rodent families (11, 12). We therefore propose that
the order of the expanded kallikrein locus is
19centromere-KLK1-PSA-KLK2-KLK frag #1-KLK frag #2-KLK4-19telomere, with the
inclusion of protease M and NES1 although the precise order and
distance of protease M and NES1 from the other KLK genes is
yet to be defined.
The human KLK gene family is clearly less conserved than its
rodent counterparts whose enzymes share 75-85% identity (10, 12, 19).
The encoded proteins of PSA and KLK2 are highly conserved (78% identity), however, they are less similar to KLK1
(52-60% identity) (3-9). KLK4 would appear to have
diverged further, being only 37% similar to PSA, KLK2, and
KLK1 and no longer containing a "kallikrein loop," a
region of 11 amino acids encoded in exon 3 and thought to be important
in the substrate specificity of these enzymes (1, 2, 7). However, the
conservation is greater at the nucleotide level (50%), as noted
previously for KLK1-3 (74-85%, Ref. 9). Of note, the
encoded protein of KLK4 is most similar to a pig enamel
matrix protease (78% identity), indicating that it is probably the
human homologue of that enzyme. Moreover, if NES1 and protease M are
also part of the human KLK gene family, along with
KLK4, they may constitute a sub-group within this family
that have diverged further in sequence from their namesake, tissue
kallikrein or KLK1.
The KLK4 gene was also recently cloned by Nelson et
al., (27) but given the name prostase because it was suggested to
be expressed specifically in the prostate. From our earlier
identification of an EST KLK4 sequence that was derived from
an endometrial carcinoma cDNA library and evidence that
KLK4 is expressed in other tissues, albeit at lower
levels,5 we would suggest
that the KLK gene family designation (34) is more
appropriate than a tissue-specific nomenclature that is difficult to
extensively verify. Similarly, the recent designation of prostase as
PRSS17,6 and thus part of a
family of serine proteases that are dispersed across several
chromosomes, also should be modified given our localization of
KLK4 (alias prostase/PRSS17) to the KLK locus. Although the function of this new gene is unknown, it is likely to be
as important in post-translational processing events as tissue
kallikrein, PSA and the K2 enzyme have proven to be in a large range of
biological events (1, 2). The reported androgen dependence of prostase
expression (26) and the putative ARE-like sequences noted here in the
5' flanking region of the KLK4 gene would support this
notion. The further characterization of the human KLK locus
is likely to provide the location of further KLK-related
genes, either known (NES1, protease M) or as yet unknown, that
will add to this diverse family of serine proteases.
We thank Dr. M. Digby for access to the work
reported in his Ph.D. Thesis, University of Melbourne, 1990.
*
This work was supported by the National Health & Medical
Research Council of Australia, Department of Veteran Affairs,
Anti-Cancer Council of Victoria, and Queensland University of
Technology. A portion of this work was performed under the U. S.
Department of Energy contract W-7405-Eng-48 at Lawrence Livermore
National Laboratory.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
The nucleotide sequence(s) reported in this paper has been submitted to the GenBankTM/EMBL Data Bank with accession number(s) AF148532.
2
The tissue kallikrein (KLK) gene
nomenclature used to identify different family members is that
recommended by a working party in 1992 (Ref. 34).
4
S. Stephenson, K. Verity, M. Digby, and J. A. Clements, unpublished observation.
5
S. Stephenson, S. Myers, F. Rae, A. Kaushal, and
J. A. Clements, unpublished observation.
6
Recent designation of the Human Gene
Nomenclature Committee.
3
Physical maps and sequences are available via
the LLNL home page.
The abbreviations used are:
KLK,
tissue kallikrein, PSA, prostate-specific antigen;
kb, kilobase pair(s);
NES1, normal epithelial cell-specific (gene) 1;
EST, expressed
sequence tag;
BACs, bacterial artificial chromosomes;
PCR, polymerase
chain reaction;
ARE, androgen regulatory element.
Localization of a New Prostate-specific Antigen-related Serine
Protease Gene, KLK4, Is Evidence for an Expanded Human
Kallikrein Gene Family Cluster on Chromosome 19q13.3-13.4*
,
§
Centre for Molecular Biotechnology, School
of Life Sciences, Queensland University of Technology, Brisbane,
Australia 4001, the § Prince Henry's Institute of Medical
Research, Clayton, Australia 3168, and the ¶ Human Genome Center,
Lawrence Livermore National Laboratory,
Livermore, California 94551
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
tissue
kallikrein (KLK1), KLK2, and prostate-specific
antigen (PSA) (KLK3)
clustered at chromosome
19q13.3-13.4. We identified an expressed sequence tag from an
endometrial carcinoma cDNA library with 50% identity to the three
known KLK genes. Primers designed to putative exon 2 and
exon 3 regions from this novel kallikrein-related sequence were used to
polymerase chain reaction-screen five cosmids spanning 130 kb around
the KLK locus on chromosome 19. This new gene, which we
have named KLK4, is 25 kb downstream of the
KLK2 gene and follows a region that includes two other
putative KLK-like gene fragments. KLK4 spans 5.2 kb, has an
identical genomic structure
five exons and four introns
to the other
KLK genes and is transcribed on the reverse strand, in the
same direction as KLK1 but opposite to that of
KLK2 and KLK3. It encodes a 254-amino acid
prepro-serine protease that is most similar (78% identical) to pig
enamel matrix serine protease but is also 37% identical to PSA. These
data suggest that the human kallikrein gene family locus on chromosome
19 is larger than previously thought and also indicate a greater
sequence divergence within this family compared with the highly
conserved rodent kallikrein genes.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
protease M (23, 24), normal epithelial cell-specific
(NES)1 gene (25, 26), and prostase (27)
with just 23-44% similarity
at the protein level to PSA or KLK1, have been identified
recently and reported to lie on chromosome 19q13.3-13.4. However,
their precise localization in relationship to the KLK locus
is not known.
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-32P]dCTP (Bresatec,
Adelaide, SA) using the Amersham Pharmacia Biotech Megaprime labeling
reaction or KLK1, KLK2, and KLK3 exon 4-specific oligonucleotide probes (KLK1, codons 142-152;
KLK2 and KLK3, codons 161-167) were end-labeled
with [
-32P]ATP (Bresatec).
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

View larger version (82K):
[in a new window]
Fig. 1.
Nucleotide sequence of the human
KLK4 gene (5'-flanking and intron segments shown in
lowercase; coding region shown in
uppercase) and the corresponding amino acid sequence
shown in single letter code. Nucleotide number and amino acid
number (in bold) are indicated to the right of
the sequence. Primers based on the EST40886 sequences (dotted
underline) and used to amplify the KLK4 genomic
fragment from cosmid F22702 are indicated with the overline
and the name of the primer. The putative start of the mature protein is
indicated by the
symbol. The amino acids that constitute the
catalytic triad (H71, D116, S207) are indicated by the * symbol and are
in bold. The stop codon is indicated by the # symbol. The
region where the kallikrein loop is deleted in the KLK4 gene
is indicated by the 
symbol. The CAA codon and Gln residue (Q) at
residue 197 that are different from the prostase sequence (26) are
indicated in bold. A putative transcriptional initiator
sequence at
35 to
21 from the ATG start site is
underlined. Potential ARE sequences in the 5'-flanking
region are indicated in bold.

View larger version (23K):
[in a new window]
Fig. 2.
Comparison of the exon and intron arrangement
of the four human kallikrein genes indicating the conservation of the
gene structure. Open boxes and single lines
indicate exons and introns, respectively. The size of each exon and
distance between exons are indicated. Untranslated sequences are not
included. Exon 1 is stippled to indicate it encodes signal
peptide only. The positions of the catalytic triad residues
(H*, D*, S*), cleavage site of the
mature enzyme (
) and kallikrein loop (
) are indicated.
35 to
21 from the ATG start site (ctaagtctcagtcc) has two
overlapping regions with similarity to the initiator sequence (ctcantct) described for a TATA-less promoter, which is often located
from
3 to +5 relative to the transcription initiator site (28), which
might be, therefore, the A nucleotide in these sequences. Although
promoter elements for PSA are located up to 6 kb from the start of the
gene (29), analysis of the 553 bp of 5'-flanking region of
KLK4 presented in Fig. 1 indicates the presence of sequences
that show partial homology to known androgen regulatory elements (AREs)
in the proximal PSA and KLK2 promoters (30, 31).
Characterization of the full promoter sequence of this gene is required
to confirm whether these are indeed functional elements.

View larger version (55K):
[in a new window]
Fig. 3.
Southern hybridization analysis of
KLK4 gene sequences in the five cosmid clones that
span the KLK locus at 19q13.3-13.4. The DNA was
digested with EcoRI and hybridized with the KLK4
cDNA sequence at high stringency. The sizes of the
HindIII-digested bacteriophage 1 standards
(M) are shown in kilobases (kb). Lanes 1 and
4, F24242; lane 2, R28297; lane 3,
F18306; lanes 5 and 7, F22702; lane 6,
R28781. The size (kb) of the strongly hybridizing bands in lanes
5-7 is indicated on the right. The fainter hybridizing
bands in lanes 1-3 are cross-hybridization of the
KLK1 and KLK3 genes located on these
cosmids.

View larger version (21K):
[in a new window]
Fig. 4.
A, EcoRI restriction map
(with sizes of EcoRI fragments indicated for each cosmid) of
the seven cosmids spanning the KLK locus on chromosome
19q13.3-13.4 used in this study. Five cosmids (F24242, R28297, F18306,
F22702, and R28781) were used for restriction mapping the position of
all four KLK genes and PCR analysis and sequencing of the
KLK4 gene. As further genomic sequencing was completed in
this region, two cosmids (indicated by asterisks on the
figure) were used to confirm the position, sequence, and orientation of
the four KLK genes. Two further small KLK-like
gene fragments (Frag #1, Frag
#2) were also identified in the region between
KLK2 and KLK4. Fig. B, corresponding
gene linkage map showing the relative locations of the human
KLK genes within the KLK locus at 19q13.3-13.4.
Intergenic sequences are indicated by single lines with the
distance in kilobases (kb). The open boxes indicate the
position and size of each KLK gene or gene fragment
(Frag #1, Frag #2). The
exact position of the KLK1 gene relative to the other
KLK genes is still to be confirmed from chromosome 19 sequence data but has been reported to be 31 kb upstream of
KLK3 (17).
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
ACKNOWLEDGEMENT
![]()
FOOTNOTES
To whom correspondence should be addressed: Centre for
Molecular Biotechnology, School of Life Sciences, Queensland University of Technology GPO Box 2434, Brisbane, Australia, 4001. Tel.:
61 7 3864 1899; Fax: 61 7 3864 1534; E-mail:
j.clements@qut.edu.au.
![]()
ABBREVIATIONS
![]()
REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
1.
Clements, J. A.
(1997)
in
The Kinin System
(Farmer, S., ed)
, pp. 72-97, Academic Press, San Diego
2.
Rittenhouse, H. G.,
Finlay, J. A.,
Mikolajczyk, S. D.,
and Partin, W.
(1998)
Crit. Rev. Clin. Lab. Sci.
35,
275-368[CrossRef][Medline]
[Order article via Infotrieve]
3.
Baker, A. R.,
and Shine, J.
(1985)
DNA
4,
445-450[Medline]
[Order article via Infotrieve]
4.
Evans, B. A.,
Yun, Z. X.,
Close, J. A.,
Tregear, G. W.,
Kitamura, N.,
Nakanishi, S.,
Callen, D. F.,
Baker, E.,
Hyland, V. J.,
Sutherland, G. R.,
and Richards, R. I.
(1988)
Biochemistry
27,
3124-3129[CrossRef][Medline]
[Order article via Infotrieve]
5.
Fukushima, D.,
Kitamura, N.,
and Nakanishi, S.
(1985)
Biochemistry
24,
8037-8043[CrossRef][Medline]
[Order article via Infotrieve]
6.
Schedlich, L. J.,
Bennetts, B. H.,
and Morris, B. J.
(1987)
DNA (N. Y.)
6,
429-437[Medline]
[Order article via Infotrieve]
7.
Lilja, H.
(1985)
J. Clin. Invest.
76,
1899-1903
8.
Reigman, P. H. J.,
Vlietstra, R. J.,
van der Korput, J. A. G. M.,
Romijin, J. C.,
and Trapman, J.
(1988)
Biochem. Biophys. Res. Commun.
159,
95-102
9.
Hentuu, P,
and Vihko, P.
(1989)
Biochem. Biophys. Res. Commun.
160,
903-910[CrossRef][Medline]
[Order article via Infotrieve]
10.
Wines, D. R.,
Brady, J. M.,
Pritchard, D. B.,
Roberts, J. L.,
and MacDonald, R. J.
(1989)
J. Biol. Chem.
264,
7653-7662 11.
Southard-Smith, M.,
Pierce, J. C.,
and MacDonald, R. J.
(1994)
Genomics
22,
404-417[CrossRef][Medline]
[Order article via Infotrieve]
12.
Evans, B.,
Drinkwater, C.,
and Richards, R.
(1987)
J. Biol. Chem.
262,
8027-8034 13.
Gerald, W. L.,
Chao, J.,
and Chao, L.
(1986)
Biochim. Biophys. Acta
866,
1-14[Medline]
[Order article via Infotrieve]
14.
Digby, M. R., and Evans, B. A. (1990) Proceedings of
the Genome Conference, Abstract POS-1-27, Lorne, Australia
15.
Riegman, P. H. J.,
Vlietstra, R. J.,
Klaassen, P.,
van der Korput, J. A. G. M.,
Geurts van Kessel, A.,
Romijin, R. C.,
and Trapman.
(1989)
FEBS Lett.
247,
123-126[CrossRef][Medline]
[Order article via Infotrieve]
16.
Murray, S. R.,
Chao, J.,
Lin, F. K.,
and Chao, L.
(1990)
J. Cardiovasc. Pharmacol.
15,
S7-S16
17.
Riegman, P. H. J.,
Vlietstra, R. J.,
Suurmeijer, L.,
Cleutjens, C. B. J. M.,
and Trapman, J.
(1992)
Genomics
14,
6-11[CrossRef][Medline]
[Order article via Infotrieve]
18.
Kurtz, T. W.,
and St. Lezin, E.
(1992)
J. Am. Soc. Nephrol.
3,
28-34[Abstract]
19.
Wines, D. R.,
Brady, J. M.,
Southard, E. M.,
and MacDonald, R. J.
(1991)
J. Mol. Evol.
32,
476-492[CrossRef][Medline]
[Order article via Infotrieve]
20.
Howles, P. N.,
Dickinson, D. P.,
DiCaprio, L. L.,
Woodworth-Gutai, M.,
and Gross, K. W.
(1984)
Nucleic Acids Res.
12,
2791-2805 21.
Murray, S. R.,
Chao, J.,
and Chao, L.
(1992)
Agents Actions
S38,
26-33
22.
Neurath, H.
(1984)
Science
224,
350-357 23.
Anisowicz, A.,
Sotiropoulou, G.,
Stenman, G.,
Mok, S. C.,
and Sager, R.
(1996)
Mol. Med.
2,
624-636[Medline]
[Order article via Infotrieve]
24.
Yamishuiro, K.,
Tsuruoka, N.,
Kodama, S.,
Tsulimoto, M.,
Yamamura, Y.,
Tanaka, T.,
Nakazato, H.,
and Yamaguchi, N.
(1997)
Biochim. Biophys. Acta
1350,
11-14[Medline]
[Order article via Infotrieve]
25.
Liu, X-L.,
Wazer, D. E.,
Watanbe, K.,
and Band, V.
(1996)
Cancer Res.
56,
3371-3379 26.
Luo, L.,
Herbrick, J. A.,
Scherer, S. W.,
Beatty, B.,
Squire, J.,
and Diamandis, E. P.
(1998)
Biochem. Biophys. Res. Commun.
247,
580-586[CrossRef][Medline]
[Order article via Infotrieve]
27.
Nelson, P. S.,
Gan, L.,
Ferguson, C.,
Moss, P.,
Gelinas, R.,
Hood, L.,
and Wang, K.
(1999)
Proc. Natl. Acad. Sci.
96,
3114-3119 28.
Adams, M. J.,
Reichel, M. B.,
King, I. A.,
Marsden, M. D.,
Greenwood, M. D.,
Thirwell, H.,
Arneman, J.,
Buxton, R. S.,
and Ali, R. R.
(1998)
Biochem. J.
329,
165-174
29.
Cleutjens, K. B. J. M.,
van der Korput, H. A. G. M.,
Ehren-van Eeklen, C. C.,
Sikes, R. A.,
Fasciana, C.,
Chung, L. W.,
and Trapman, J.
(1997)
Mol. Endocrinol.
11,
1256-1265 30.
Riegman, P. H. J.,
Vliestra, R. J.,
van der Korput, J. A. G. M,
Brinkmann, A. O.,
and Trapman, J.
(1991)
Mol. Endocrinol.
5,
1921-1930[CrossRef][Medline]
[Order article via Infotrieve]
31.
Cleutjens, K. B. J. M.,
van Eekelen, C. C. E. M.,
van der Korput, H. A. G. M.,
Brinkmann, A. O.,
and Trapman, J.
(1996)
J. Biol. Chem.
271,
6379-6388 32.
Irwin, D. M.
(1988)
Nature
336,
429-430[Medline]
[Order article via Infotrieve]
33.
Schedlich, L. J.,
and Morris, B. J.
(1988)
Clin. Exp. Pharm. Phys.
15,
339-344[Medline]
[Order article via Infotrieve]
34.
Berg, T.,
Bradshaw, R. A.,
Carretero, O. A.,
Chao, J.,
Chao, L.,
Clements, J. A.,
Fahnestock, M.,
Fritz, H.,
Gauthier, F.,
MacDonald, R. J.,
Margolius, H. S.,
Morris, B. J.,
Richards, R. I.,
and Scicli, A. G.
(1992)
in
Recent Progress on Kinins
(Fritz, H.
, Muller-Esterl, W.
, Jochum, M.
, Roscher, A.
, and Luppertz, K., eds), Vol. I
, pp. 19-25, Birkhauser Verlag, Basel
Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
A. J. Ramsay, Y. Dong, M. L. Hunt, M. Linn, H. Samaratunga, J. A. Clements, and J. D. Hooper Kallikrein-related Peptidase 4 (KLK4) Initiates Intracellular Signaling via Protease-activated Receptors (PARs): KLK4 AND PAR-2 ARE CO-EXPRESSED DURING PROSTATE CANCER PROGRESSION J. Biol. Chem., May 2, 2008; 283(18): 12293 - 12304. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. I. Klokk, A. Kilander, Z. Xi, H. Waehre, B. Risberg, H. E. Danielsen, and F. Saatcioglu Kallikrein 4 Is a Proliferative Factor that Is Overexpressed in Prostate Cancer Cancer Res., June 1, 2007; 67(11): 5221 - 5230. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y Dong, L T Bui, D M Odorico, O L Tan, S A Myers, H Samaratunga, R A Gardiner, and J A Clements Compartmentalized expression of kallikrein 4 (KLK4/hK4) isoforms in prostate cancer: nuclear, cytoplasmic and secreted forms Endocr. Relat. Cancer, December 1, 2005; 12(4): 875 - 889. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Stephanopoulos, M.-E. Garefalaki, and K. Lyroudia Genes and Related Proteins Involved in Amelogenesis Imperfecta J. Dent. Res., December 1, 2005; 84(12): 1117 - 1126. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. V. Obiezu, S. J.C. Shan, A. Soosaipillai, L.-Y. Luo, L. Grass, G. Sotiropoulou, C. D. Petraki, P. A. Papanastasiou, M. A. Levesque, and E. P. Diamandis Human Kallikrein 4: Quantitative Study in Tissues and Evidence for Its Secretion into Biological Fluids Clin. Chem., August 1, 2005; 51(8): 1432 - 1442. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. P. Simmer, J. D. Bartlett, and F. Saatcioglu Kallikrein 4 Is a Secreted Protein Cancer Res., November 15, 2004; 64(22): 8481 - 8483. [Full Text] [PDF] |
||||
![]() |
P S Hart, T C Hart, M D Michalec, O H Ryu, D Simmons, S Hong, and J T Wright Mutation in kallikrein 4 causes autosomal recessive hypomaturation amelogenesis imperfecta J. Med. Genet., July 1, 2004; 41(7): 545 - 549. [Full Text] [PDF] |
||||
![]() |
C. A. Borgono, I. P. Michael, and E. P. Diamandis Human Tissue Kallikreins: Physiologic Roles and Applications in Cancer Mol. Cancer Res., May 1, 2004; 2(5): 257 - 280. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Xi, T. I. Klokk, K. Korkmaz, P. Kurys, C. Elbi, B. Risberg, H. Danielsen, M. Loda, and F. Saatcioglu Kallikrein 4 is a Predominantly Nuclear Protein and Is Overexpressed in Prostate Cancer Cancer Res., April 1, 2004; 64(7): 2365 - 2370. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. V. Obiezu, A. Soosaipillai, K. Jung, C. Stephan, A. Scorilas, D. H. C. Howarth, and E. P. Diamandis Detection of Human Kallikrein 4 in Healthy and Cancerous Prostatic Tissues by Immunofluorometry and Immunohistochemistry Clin. Chem., August 1, 2002; 48(8): 1232 - 1240. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Hural, R. S. Friedman, A. McNabb, S. S. Steen, R. A. Henderson, and M. Kalos Identification of Naturally Processed CD4 T Cell Epitopes from the Prostate-Specific Antigen Kallikrein 4 Using Peptide-Based In Vitro Stimulation J. Immunol., July 1, 2002; 169(1): 557 - 565. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Matsui and T. Takahashi Mouse Testicular Leydig Cells Express Klk21, a Tissue Kallikrein That Cleaves Fibronectin and IGF-Binding Protein-3 Endocrinology, November 1, 2001; 142(11): 4918 - 4929. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Dong, A. Kaushal, L. Bui, S. Chu, P. J. Fuller, J. Nicklin, H. Samaratunga, and J. A. Clements Human Kallikrein 4 (KLK4) Is Highly Expressed in Serous Ovarian Carcinomas Clin. Cancer Res., August 1, 2001; 7(8): 2363 - 2371. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. V. Obiezu, A. Scorilas, D. Katsaros, M. Massobrio, G. M. Yousef, S. Fracchioli, I. A. Rigault de la Longrais, R. Arisio, and E. P. Diamandis Higher Human Kallikrein Gene 4 (KLK4) Expression Indicates Poor Prognosis of Ovarian Cancer Patients Clin. Cancer Res., August 1, 2001; 7(8): 2380 - 2386. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. M. Yousef and E. P. Diamandis The New Human Tissue Kallikrein Gene Family: Structure, Function, and Association to Disease Endocr. Rev., April 1, 2001; 22(2): 184 - 204. [Abstract] [Full Text] |
||||
![]() |
E. P. Diamandis, G. M. Yousef, J. Clements, L. K. Ashworth, S. Yoshida, T. Egelrud, P. S. Nelson, S. Shiosaka, S. Little, H. Lilja, et al. New Nomenclature for the Human Tissue Kallikrein Gene Family Clin. Chem., November 1, 2000; 46(11): 1855 - 1858. [Full Text] [PDF] |
||||
![]() |
E. P. Diamandis Prostate-specific Antigen: A Cancer Fighter and a Valuable Messenger? Clin. Chem., July 1, 2000; 46(7): 896 - 900. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. J. Harvey, J. D. Hooper, S. A. Myers, S.-A. Stephenson, L. K. Ashworth, and J. A. Clements Tissue-specific Expression Patterns and Fine Mapping of the Human Kallikrein (KLK) Locus on Proximal 19q13.4 J. Biol. Chem., November 22, 2000; 275(48): 37397 - 37406. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. M. Yousef, A. Scorilas, K. Jung, L. K. Ashworth, and E. P. Diamandis Molecular Cloning of the Human Kallikrein 15 Gene (KLK15). UP-REGULATION IN PROSTATE CANCER J. Biol. Chem., January 5, 2001; 276(1): 53 - 61. [Abstract] [Full Text] [PDF] |
||||
| ||||||